Jefferies analyst Lucy Codrington maintained a Buy rating on Zealand Pharma (ZLDPF – Research Report) on June 28 and set a price target of DKK1,100.00. The company’s shares closed last Friday at $129.35.

According to TipRanks, Codrington is ranked #2487 out of 8870 analysts.

Zealand Pharma has an analyst consensus of Strong Buy, with a price target consensus of $129.36, which is a 0.01% upside from current levels. In a report released on June 24, BTIG also maintained a Buy rating on the stock with a DKK950.00 price target.

The company has a one-year high of $129.35 and a one-year low of $31.81. Currently, Zealand Pharma has an average volume of 1,948.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Zealand Pharma (ZLDPF) Company Description:

Zealand Pharma A/S is a biotechnology company that engages in the discovery, design and development of peptide based medicines. Its products include Soliqua and Lyxumia. The company was founded by Lars Hellerung Christiansen and Bjarne Due Larsen on October 19, 1998 and is headquartered in Glostrup, Denmark.

ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xopZ6vo2TAtbvCpKpoopWbs6a%2ByJ6qZqqVoq6qutJmmGaapa56sLqMs5yapJGjsW68x5qpppldr7mlvMVmaGlrY2p%2BeH%2BQbQ%3D%3D